<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00500266</url>
  </required_header>
  <id_info>
    <org_study_id>6115A1-3000</org_study_id>
    <nct_id>NCT00500266</nct_id>
  </id_info>
  <brief_title>Study Evaluating Safety of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Elderly Subjects</brief_title>
  <official_title>A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, &amp; Reactogenicity of a 13vPnC Vaccine in Ambulatory Elderly Adults Aged 68 Years &amp; Older Who Received 1 or More Doses of 23vPS Vaccine at Least 3 Years Before Study Enrollment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety of 13-valent pneumococcal conjugate vaccine (13vPnC) in elderly
      subjects who were vaccinated with one or more doses of 23-valent pneumococcal polysaccharide
      vaccine (23vPS) at least 3 years before study enrollment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Pre-specified Local Reactions</measure>
    <time_frame>Days 1 through 14</time_frame>
    <description>Local reactions were collected by the participant using an electronic diary. Redness and swelling scaled as any(present); mild(2.5-5.0 centimeters[cm]); moderate(5.1-10.0 cm); severe(&gt;10.0cm). Pain as any(present); mild(present, no interference with activity); moderate(present, some interference with activity); severe(present, prevents daily activity). Limitation of arm movement as any(present); mild(present, could move arm above head); moderate(could move arm above shoulder but not above head); severe(could not move arm above shoulder). Participants may be represented in more than 1 category.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Pre-specified Systemic Events</measure>
    <time_frame>Days 1 through 14</time_frame>
    <description>Systemic events were collected by participant using electronic diary. Fatigue,headache,new/aggravated generalized muscle pain,new/aggravated generalized joint pain: any, mild(no interference with activity), moderate(some interference with activity), severe(prevents routine daily activity). Fever(&gt;=38 degrees Celsius[C]), chills, rash, vomiting(mild:1-2 times daily; moderate:&gt;2 times daily; severe:prevents daily activity) decreased appetite &amp; diarrhea(mild:2-3 loose stools/day; moderate:4-5 loose stools/day; severe:&gt;=6 loose stools/day) reported. Participants may be represented in &gt;1 category.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Taking Pain or Antipyretic Medication</measure>
    <time_frame>Days 1 through 14</time_frame>
    <description>Use of pain or antipyretic medication was collected by the participants using an electronic diary.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1053</enrollment>
  <condition>Pneumococcal Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>13-valent Pneumococcal Conjugate Vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>13-valent Pneumococcal Conjugate Vaccine (13vPnC)</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        MAIN INCLUSION CRITERIA:

          -  Male or female aged 68 years or older

          -  Determined by medical history, physical examination, and clinical judgment to be
             eligible for the study

          -  Documented vaccination with 1 or more doses of pneumococcal vaccine at least 3 years
             before study enrollment

        MAIN EXCLUSION CRITERIA:

          -  Known history of severe reaction to a vaccine

          -  Documented S pneumoniae infection within the past 5 years.

          -  Known or suspected immunodeficiency or receiving treatment with immunosuppressive
             therapy including cytotoxic agents or systemic corticosteroids

          -  Serious chronic disorder including metastatic malignancy, severe chronic obstructive
             pulmonary disease requiring supplemental oxygen, end-stage renal disease with or
             without dialysis, clinically unstable cardiac disease, or any other disorder that in
             the investigator's opinion precludes the subject from participating in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>68 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rolling Hills Estates</city>
        <state>California</state>
        <zip>90274</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Apopka</city>
        <state>Florida</state>
        <zip>32703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chiefland</city>
        <state>Florida</state>
        <zip>32626</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32935</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arkansas City</city>
        <state>Kansas</state>
        <zip>67005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Crescent Springs</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nitchitoches</city>
        <state>Louisiana</state>
        <zip>71547</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Camillus</city>
        <state>New York</state>
        <zip>13031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Canal Fulton</city>
        <state>Ohio</state>
        <zip>44614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Franklin</city>
        <state>Ohio</state>
        <zip>45005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goose Creek</city>
        <state>South Carolina</state>
        <zip>29445</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mt Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bellingham</city>
        <state>Virginia</state>
        <zip>98226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Walla Walla</city>
        <state>Washington</state>
        <zip>99362</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <zip>98801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin-Charlottenburg</city>
        <zip>14059</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin-Wilmersdorf</city>
        <zip>10717</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>10717</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>10969</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Deggingen</city>
        <zip>73326</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt-am-Main</city>
        <zip>60322</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kassel</city>
        <zip>34121</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leipzig</city>
        <zip>04357</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Offenbach</city>
        <zip>63071</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wangen</city>
        <zip>88239</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wuerzburg</city>
        <zip>97070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arlov</city>
        <zip>23234</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gothenburg</city>
        <zip>41136</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Skene</city>
        <zip>51162</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Skivarp</city>
        <zip>27402</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <zip>11136</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Umea</city>
        <zip>90736</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2007</study_first_submitted>
  <study_first_submitted_qc>July 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2007</study_first_posted>
  <results_first_submitted>August 11, 2011</results_first_submitted>
  <results_first_submitted_qc>August 11, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 16, 2011</results_first_posted>
  <disposition_first_submitted>March 2, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>March 2, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 3, 2010</disposition_first_posted>
  <last_update_submitted>August 11, 2011</last_update_submitted>
  <last_update_submitted_qc>August 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2011</last_update_posted>
  <responsible_party>
    <name_title>Wyeth (Registry Contact: Clinical Trial Registry Specialist)</name_title>
    <organization>Wyeth</organization>
  </responsible_party>
  <keyword>pneumococcal conjugate vaccine</keyword>
  <keyword>vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>13vPnC</title>
          <description>Participants received single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) into the deltoid muscle of the arm.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1053"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="1049"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1040"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Assigned, not treated</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>13vPnC</title>
          <description>Participants received single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) into the deltoid muscle of the arm.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1049"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.3" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="584"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="465"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Pre-specified Local Reactions</title>
        <description>Local reactions were collected by the participant using an electronic diary. Redness and swelling scaled as any(present); mild(2.5-5.0 centimeters[cm]); moderate(5.1-10.0 cm); severe(&gt;10.0cm). Pain as any(present); mild(present, no interference with activity); moderate(present, some interference with activity); severe(present, prevents daily activity). Limitation of arm movement as any(present); mild(present, could move arm above head); moderate(could move arm above shoulder but not above head); severe(could not move arm above shoulder). Participants may be represented in more than 1 category.</description>
        <time_frame>Days 1 through 14</time_frame>
        <population>Safety population: all participants who received 1 dose of 13vPnC. n = participants reporting “yes” for at least 1 day or “no” for all days.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>Participants received single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) into the deltoid muscle of the arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Pre-specified Local Reactions</title>
          <description>Local reactions were collected by the participant using an electronic diary. Redness and swelling scaled as any(present); mild(2.5-5.0 centimeters[cm]); moderate(5.1-10.0 cm); severe(&gt;10.0cm). Pain as any(present); mild(present, no interference with activity); moderate(present, some interference with activity); severe(present, prevents daily activity). Limitation of arm movement as any(present); mild(present, could move arm above head); moderate(could move arm above shoulder but not above head); severe(could not move arm above shoulder). Participants may be represented in more than 1 category.</description>
          <population>Safety population: all participants who received 1 dose of 13vPnC. n = participants reporting “yes” for at least 1 day or “no” for all days.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1049"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Redness: Any (n=666)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" lower_limit="11.7" upper_limit="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Mild (n=660)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6" lower_limit="10.1" upper_limit="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Moderate (n=649)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" lower_limit="4.7" upper_limit="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Severe (n=638)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="0.4" upper_limit="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any (n=664)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8" lower_limit="10.4" upper_limit="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Mild (n=658)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9" lower_limit="8.7" upper_limit="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Moderate (n=651)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" lower_limit="3.9" upper_limit="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Severe (n=636)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="0.2" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Any (n=777)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.0" lower_limit="47.4" upper_limit="54.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Mild (n=770)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.4" lower_limit="45.8" upper_limit="52.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Moderate (n=656)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" lower_limit="6.9" upper_limit="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Severe (n=634)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="0.0" upper_limit="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Any (n=679)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.2" lower_limit="13.5" upper_limit="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Mild (n=674)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8" lower_limit="12.2" upper_limit="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Moderate (n=636)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="0.8" upper_limit="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Severe (n=640)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="0.8" upper_limit="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any local reaction (n=802)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.6" lower_limit="53.1" upper_limit="60.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any severe local reaction (n=643)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="1.5" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Pre-specified Systemic Events</title>
        <description>Systemic events were collected by participant using electronic diary. Fatigue,headache,new/aggravated generalized muscle pain,new/aggravated generalized joint pain: any, mild(no interference with activity), moderate(some interference with activity), severe(prevents routine daily activity). Fever(&gt;=38 degrees Celsius[C]), chills, rash, vomiting(mild:1-2 times daily; moderate:&gt;2 times daily; severe:prevents daily activity) decreased appetite &amp; diarrhea(mild:2-3 loose stools/day; moderate:4-5 loose stools/day; severe:&gt;=6 loose stools/day) reported. Participants may be represented in &gt;1 category.</description>
        <time_frame>Days 1 through 14</time_frame>
        <population>Safety population: all participants who received 1 dose of 13vPnC. n = number of participants with the event as “yes” for at least 1 day or as “no” for all days.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>Participants received single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) into the deltoid muscle of the arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Pre-specified Systemic Events</title>
          <description>Systemic events were collected by participant using electronic diary. Fatigue,headache,new/aggravated generalized muscle pain,new/aggravated generalized joint pain: any, mild(no interference with activity), moderate(some interference with activity), severe(prevents routine daily activity). Fever(&gt;=38 degrees Celsius[C]), chills, rash, vomiting(mild:1-2 times daily; moderate:&gt;2 times daily; severe:prevents daily activity) decreased appetite &amp; diarrhea(mild:2-3 loose stools/day; moderate:4-5 loose stools/day; severe:&gt;=6 loose stools/day) reported. Participants may be represented in &gt;1 category.</description>
          <population>Safety population: all participants who received 1 dose of 13vPnC. n = number of participants with the event as “yes” for at least 1 day or as “no” for all days.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1049"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever (any): &gt;=38 degrees C (n=641)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.1" upper_limit="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: &gt;=38 degrees C but &lt;38.5 degrees C (n=636)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="0.3" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: &gt;=38.5 degrees C but &lt;39 degrees C (n=634)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: &gt;=39 degrees C but &lt;=40 degrees C (n=635)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0.0" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: &gt;40 degrees C (n=638)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="0.3" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Any (n=733)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.4" lower_limit="30.9" upper_limit="37.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Mild (n=710)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.7" lower_limit="25.4" upper_limit="32.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Moderate (n=683)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.2" lower_limit="12.6" upper_limit="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Severe (n=639)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.1" upper_limit="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Any (n=702)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.1" lower_limit="22.9" upper_limit="29.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Mild (n=696)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.1" lower_limit="21.0" upper_limit="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Moderate (n=655)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" lower_limit="6.9" upper_limit="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Severe (n=637)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="0.3" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills (n=651)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" lower_limit="5.6" upper_limit="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash (n=658)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4" lower_limit="6.4" upper_limit="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Any (vomiting present; n=638)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="0.3" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Mild (1 to 2 times in 24 hours;n=637)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="0.3" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Moderate (&gt;2 times in 24 hours;n=635)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="0.0" upper_limit="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Severe (prevents routine activity;n=634)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite (n=668)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" lower_limit="8.9" upper_limit="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Any (diarrhea present; n=684)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" lower_limit="11.9" upper_limit="17.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Mild (2 to 3 loose stools/day; n=678)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8" lower_limit="10.4" upper_limit="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Moderate (4 to 5 loose stools/day;n=644)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" lower_limit="2.2" upper_limit="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Severe (&gt;=6 loose stools/day; n=635)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0.0" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New generalized muscle pain: Any (n=700)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.3" lower_limit="22.1" upper_limit="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New generalized muscle pain: Mild (n=679)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5" lower_limit="17.5" upper_limit="23.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New generalized muscle pain: Moderate (n=658)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" lower_limit="6.0" upper_limit="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New generalized muscle pain: Severe (n=636)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="0.2" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aggravated generalized muscle pain: Any (n=669)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3" lower_limit="9.9" upper_limit="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aggravated generalized muscle pain: Mild (n=650)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" lower_limit="5.6" upper_limit="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aggravated generalized muscle pain:Moderate(n=655)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" lower_limit="4.7" upper_limit="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aggravated generalized muscle pain: Severe (n=639)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="0.6" upper_limit="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New generalized joint pain: Any (n=665)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8" lower_limit="10.3" upper_limit="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New generalized joint pain: Mild (n=651)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" lower_limit="6.2" upper_limit="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New generalized joint pain: Moderate (n=648)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" lower_limit="4.1" upper_limit="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New generalized joint pain: Severe (n=637)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="0.3" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aggravated generalized joint pain: Any (n=661)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7" lower_limit="7.5" upper_limit="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aggravated generalized joint pain: Mild (n=647)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" lower_limit="4.1" upper_limit="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aggravated generalized joint pain: Moderate(n=647)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" lower_limit="3.5" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aggravated generalized joint pain: Severe (n=637)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="0.4" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any systemic event (n=832)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.4" lower_limit="55.0" upper_limit="61.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Taking Pain or Antipyretic Medication</title>
        <description>Use of pain or antipyretic medication was collected by the participants using an electronic diary.</description>
        <time_frame>Days 1 through 14</time_frame>
        <population>Safety population: all participants who received 1 dose of 13vPnC. n = number of participants with the event as “yes” for at least 1 day or as “no” for all days.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>Participants received single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) into the deltoid muscle of the arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Taking Pain or Antipyretic Medication</title>
          <description>Use of pain or antipyretic medication was collected by the participants using an electronic diary.</description>
          <population>Safety population: all participants who received 1 dose of 13vPnC. n = number of participants with the event as “yes” for at least 1 day or as “no” for all days.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1049"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Use of medication to treat pain (n=677)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.0" lower_limit="14.2" upper_limit="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use of medication to treat fever (n=655)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" lower_limit="4.7" upper_limit="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Local reactions, systemic events recorded within 14 days post vaccination. AEs recorded from Visit(V) 1 to 2(29-43 days after V1). At V3(166-194 days after V1), only newly diagnosed chronic medical conditions recorded as AEs. SAEs recorded from V1 to V3.</time_frame>
      <desc>Local reactions and systemic events were collected by the participants using an electronic diary checklist (systematic assessment). AE/SAEs were documented by investigator on the case report form (non-systematic assessment) at each visit.</desc>
      <group_list>
        <group group_id="E1">
          <title>13vPnC: Visit 1 to Visit 2</title>
          <description>Participants received a single 0.5 mL dose of 13vPnC into the deltoid muscle of the arm once during the study. Local reactions and systemic events were collected from Day 1 through Day 14. AEs were recorded from Visit 1 to Visit 2 (29-43 days after Visit 1). SAEs were collected throughout the study.</description>
        </group>
        <group group_id="E2">
          <title>13vPnC: 6-month Follow-up</title>
          <description>Participants received a single 0.5 mL dose of 13vPnC into the deltoid muscle of the arm once during the study. At visit 3, the 6-month follow-up (166-194 days after Visit 1) only newly diagnosed chronic medical conditions were collected as AEs. SAEs were collected throughout the study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="1049"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Fracture displacement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Postoperative renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Breast cancer in situ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Fibrosarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Renal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Guillain-Barre syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Percutaneous coronary intervention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="486" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="1049"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Left ventricular hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Tricuspid valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Deafness neurosensory</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1049"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Retching</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1049"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title vocab="Systemic events">Fever (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Fever (any) = ≥38 degrees C</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="641"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fever (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Fever (mild) = ≥38 degrees C but &lt;38.5 degrees C</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="636"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fever (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Fever (moderate) = ≥38.5 degrees C but &lt;39 degrees C.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="634"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fever (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Fever (severe) = ≥39 degrees C but ≤40 degrees C</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="635"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fever (potentially life threatening)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Fever (potentially life threatening) = &gt;40 degrees C</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="638"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fatigue (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Fatigue (any) = fatigue present</description>
                <counts group_id="E1" subjects_affected="252" subjects_at_risk="733"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fatigue (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Fatigue (mild) = no interference with activity.</description>
                <counts group_id="E1" subjects_affected="204" subjects_at_risk="710"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fatigue (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Fatigue (moderate) = some interference with activity.</description>
                <counts group_id="E1" subjects_affected="104" subjects_at_risk="683"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fatigue (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Fatigue (severe) = prevents routine daily activity.</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="639"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Headache (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Headache (any) = headache present.</description>
                <counts group_id="E1" subjects_affected="183" subjects_at_risk="702"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Headache (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Headache (mild) = no interference with activity.</description>
                <counts group_id="E1" subjects_affected="168" subjects_at_risk="696"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Headache (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Headache (moderate) = some interference with activity.</description>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Headache (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Headache (severe) = prevents routine daily activity.</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="637"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Chills</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="651"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Rash</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="658"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Vomiting (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Vomiting (any) = vomiting present.</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="638"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Vomiting (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Vomiting (mild) = no interference with activity or 1 to 2 times in 24 hours.</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="637"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Vomiting (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Vomiting (moderate) = some interference with activity or more than 2 times in 24 hours.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="635"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Vomiting (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Vomiting (severe) = prevents routine daily activity.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="634"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="668"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Diarrhea (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Diarrhea (any) = diarrhea present.</description>
                <counts group_id="E1" subjects_affected="99" subjects_at_risk="684"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Diarrhea (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Diarrhea (mild) = 2 to 3 loose stools in 24 hours.</description>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="678"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Diarrhea (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Diarrhea (moderate) = 4 to 5 loose stools in 24 hours.</description>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="644"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Diarrhea (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Diarrhea (severe) = 6 or more loose stools in 24 hours.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="635"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">New generalized muscle pain (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>New generalized muscle pain (any) = new generalized muscle pain present.</description>
                <counts group_id="E1" subjects_affected="177" subjects_at_risk="700"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">New generalized muscle pain (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>New generalized muscle pain (mild) = no interference with activity.</description>
                <counts group_id="E1" subjects_affected="139" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">New generalized muscle pain (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>New generalized muscle pain (moderate) = some interference with activity.</description>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="658"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">New generalized muscle pain (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>New generalized muscle pain (severe) = prevents routine daily activity.</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="636"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Aggravated generalized muscle pain (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Aggravated generalized muscle pain (any) = aggravated generalized muscle pain present.</description>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="669"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Aggravated generalized muscle pain (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Aggravated generalized muscle pain (mild) = no interference with activity.</description>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="650"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Aggravated generalized muscle pain (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Aggravated generalized muscle pain (moderate) = some interference with activity.</description>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Aggravated generalized muscle pain (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Aggravated generalized muscle pain (severe) = prevents routine daily activity.</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="639"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">New generalized joint pain (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>New generalized joint pain (any) = new generalized joint pain present.</description>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="665"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">New generalized joint pain (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>New generalized joint pain (mild) = no interference with activity.</description>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="651"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">New generalized joint pain (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>New generalized joint pain (moderate) = some interference with activity.</description>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="648"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">New generalized joint pain (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>New generalized joint pain (severe) = prevents routine daily activity.</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="637"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Aggravated generalized joint pain (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Aggravated generalized joint pain (any) = aggravated generalized joint pain present.</description>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="661"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Aggravated generalized joint pain (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Aggravated generalized joint pain (mild) = no interference with activity.</description>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Aggravated generalized joint pain (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Aggravated generalized joint pain (moderate) = some interference with activity.</description>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="647"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Aggravated generalized joint pain (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Aggravated generalized joint pain (severe) = prevents routine daily activity.</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="637"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Injection site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Suprapubic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Nail infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Staphylococcal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Tinea cruris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Electric shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Blood thyroid stimulating hormone increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Glucose tolerance impaired</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Musculoskeletal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Plantar fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Osteopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Joint range of motion decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Sacroiliitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign breast neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Endobronchial lipoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Meningioma benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Narcolepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Restless legs syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Stress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder spasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Hypertonic bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Renal mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Atrophic vulvovaginitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title vocab="Local reactions">Redness (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Redness (any) = present at site of vaccination.</description>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="666"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Redness (mild) = 2.5 to 5.0 cm</description>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="660"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Redness (moderate) = 5.1 to 10.0 cm</description>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="649"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (severe)</sub_title>
                <description>Redness (severe) = &gt;10.0 cm</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="638"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Swelling (any) = present at site of vaccination</description>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="664"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Swelling (mild) = 2.5 to 5.0 cm</description>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="658"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Swelling (moderate) = 5.1 to 10.0 cm</description>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="651"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Swelling (severe) = 10.0 cm</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="636"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Pain (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Pain (any) = present at site of vaccination.</description>
                <counts group_id="E1" subjects_affected="396" subjects_at_risk="777"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Pain (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Pain (mild) = no interference with activity.</description>
                <counts group_id="E1" subjects_affected="380" subjects_at_risk="770"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Pain (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Pain (moderate) = some interference with activity.</description>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="656"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Pain (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Pain (severe) = prevents routine daily activity.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="634"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Limitation of arm movement (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Limitation of arm movement (any) = present due to vaccination.</description>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="679"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Limitation of arm movement (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Limitation of arm movement (mild) = some limitation of arm movement.</description>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="674"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Limitation of arm movement (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Limitation of arm movement (moderate) = unable to move arm above head but able to move arm above shoulder.</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="636"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Limitation of arm movement (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Limitation of arm movement (severe) = unable to move arm above shoulder.</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="640"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Actinic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Intertrigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Skin discolouration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Skin mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Milia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Joint prosthesis user</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
              <event>
                <sub_title>Temporal arteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1049"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1049"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

